论文部分内容阅读
目的比较雷贝拉唑钠肠溶片与奥美拉唑镁片三联疗法根除幽门螺杆菌(Hp)感染的疗效,以指导临床用药。方法经内镜组织病理学确诊为Hp阳性的病例,随机分为2组,A组:奥美拉唑镁片20mg每日2次,加替沙星片0.2g每日2次,呋喃唑酮片0.1g每日2次;B组:雷贝拉唑钠肠溶片10mg每日2次,加替沙星片0.2g每日2次,呋喃唑酮片0.1g每日2次,共1周。4周后复查14C呼气试验。结果雷贝拉唑钠肠溶片三联疗法和奥美拉唑镁片三联疗法Hp根除率分别达到95.5%和92.6%(P>0.05)。雷贝拉唑钠肠溶片三联疗法发生纳差1例;奥美拉唑镁片三联疗法2例发生轻度不良反应,其中纳差1例,恶心1例,均能耐受。结论雷贝拉唑钠肠溶片及奥美拉唑镁片三联疗法均能有效根除Hp,且雷贝拉唑钠肠溶片三联疗法具有较好性价比,是理想的临床用药。
Objective To compare the efficacy of rabeprazole sodium enteric-coated tablets and omeprazole magnesium tablets in the treatment of Helicobacter pylori (Hp) infection in order to guide clinical medication. Methods Hp positive cases diagnosed by endoscopic histopathology were randomly divided into two groups. Group A: omeprazole magnesium tablets 20mg twice daily, gatifloxacin tablets 0.2g twice daily, furazolidone tablets 0.1 g twice daily; group B: rabeprazole sodium enteric-coated tablets 10mg twice daily, gatifloxacin tablets 0.2g twice daily, furazolidone tablets 0.1g twice daily for 1 week. Review 14C breath test after 4 weeks. Results The eradication rates of rabeprazole sodium enteric-coated tablets triple therapy and omeprazole magnesium tablets triple therapy were 95.5% and 92.6%, respectively (P> 0.05). Rabeprazole sodium enteric-coated triple therapy in patients with anorexia occurred in 1 case; omeprazole magnesium triple therapy in patients with mild adverse reactions, including 1 case of anorexia, nausea in 1 case, can tolerate. Conclusion Rabeprazole sodium enteric-coated tablets and omeprazole magnesium tablets triple therapy can effectively eradicate Hp, and rabeprazole sodium enteric-coated triple therapy has good cost performance, is the ideal clinical drug.